Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization.
Freund
D A
DA
School of Public and Environmental Affairs, Department of Medicine and Family Medicine, Bowen Research Center, Indiana University, Bloomington 47405, USA.
Dittus
R S
RS
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004311:Double-Blind Method; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D010045:Outpatients; D016032:Randomized Controlled Trials as Topic / Q000191:economics*; D011994:Recombinant Proteins / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D003630:Daunorubicin